Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 December 2024 | Story André Damons | Photo André Damons
Dr Innocensia Mangoato
Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. Here she is with her supervisor and mentor Prof Motlalepula Matsabisa, Director of the University of the Free State (UFS) Department of Pharmacology.

A lecturer and researcher from the University of the Free State (UFS) Department of Pharmacology hopes her research into the use of cannabis in reversing anticancer drug resistance is a step forward into treating various cancers especially in Southern Africa.

Dr Innocensia Mangoato graduated on Tuesday (10 December 2024) with the degree Doctor of Philosophy with specialisation in pharmacology at the Faculty of Health Sciences’ December graduation ceremony. She started her career as a research scientist in the area of African traditional medicines in 2018 and her research received both national and international recognition.

“It’s an amazing (feeling to graduate today). My PhD journey was smooth and beautiful and with mentorship of Prof (Motlalepula) Matsabisa, who groomed me well, I did not shed a tear,” said Dr Mangoato. Dr Gudrun S Ulrich-Merzenich from the University of Bonn in Germany, was her co-supervisor with Prof Matsabisa.

According to the graduation programme, Dr Mangoato, Lecturer and Researcher in the UFS Department of Pharmacology, with her thesis titled Investigating the anticancer and possible resistant reversal effects of cannabis sativa l. extracts in cervical cancer cell lines and modulation of ABC transporters comprehensively explored the therapeutic potential of Cannabis sativa L. in overcoming drug resistance in cervical cancer using in vitro and network pharmacology approaches.

A step forward for treating various cancers

The research looked at the chemical fingerprints and pharmacological targets of C. sativa L. extracts, highlighting its antiproliferative properties against normal non-cancerous cells, cervical cancer cells and the cisplatin-resistant cervical cancer cells. Through PCR analysis, distinct gene expression profiles were identified, revealing the potential effects of combination treatments to counteract cisplatin resistance by downregulating genes associated with drug transporters and crucial signalling pathways. This work provides valuable insights into innovative therapeutic strategies for improving cervical cancer treatment, highlighting new avenues for overcoming resistance and enhancing treatment efficacy though the possible use of plant extracts.

“I hope my research takes a step forward in treating various cancers – especially gynaecology cancers in the Southern Hemisphere in Africa. Hopefully the research can later transcend into clinical trials and hopefully influence more policymakers. We also hope to further develop cannabis to be used as an adjuvant therapy for those drugs that are failing to treat cancer,” says Dr Mangoato, who was the recipient of the Women in Science Master’s Student in 2018.

Her graduation was also a proud moment for Prof Matsabisa, an expert in traditional African medicine, who was like a father to her during her studies. “Prof identified me from my honours degree and walked this journey with me. He has been a great mentor, a father and an amazing supervisor.”

Dr Mangoato says she will for now focus on research only and helping and monitoring upcoming researchers, especially female researchers as there is a scarcity of them her field. 

News Archive

UFS becomes partner of national bursary competition for the performing arts
2008-11-28

The Department of Drama and Theatre Arts at the University of the Free State (UFS) has become a partner of the Arts & Culture Trust (ACT) and the Dramatic, Artistic, and Literary Rights Organisation’s (DALRO) new bursary programme for the performing arts.

The ACT DALRO Scholarship Programme will be implemented for the first time in 2009. For the following three years (2009-2011) one learner will receive
R75 000 per year that will be used to pay for his/her studies to an accredited undergraduate tertiary institution of their choice in the performing arts.

Grade 12 learners are invited to participate in the national competition where their abilities to act, sing and dance will be judged. Individuals who already matriculated and who are not registered for a formal course in the performing arts, are also encouraged to participate. Schools, drama clubs and colleges may also register a group of learners.

An elimination round of the competition will take place next year on 21 and 22 July 2009 at the Scaena Theatre on the UFS Main Campus in Bloemfontein.

The registration fee is R200 per participant and a limited number of registrations will be subsidised. The closing date for the applications for subsidies is 31 March 2009 and registration of individuals and/or organisations is 30 April 2009.

Register at the Department of Drama and Theatre Arts at the UFS or fax the necessary documents to 051 401 3494. Application forms, rules and requirements to prepare for the competition can be requested from kamperm.hum@ufs.ac.za or fax a request to 051 401 3493.

Finalists must be available for the final round that will take place in September 2009 in Johannesburg. ACT will carry the cost of the transport and accommodation of the finalists for the final round.

Ms Marijda Kamper can be contacted at 051 401 2160 or kamperm.hum@ufs.ac.za  for more information regarding the Free State round. Mr Pieter Jacobs can be contacted at 011 802 7646 or pieter@act.org.za for general enquiries about the ACT Programme, or visit www.act.org.za .


Media Release
Issued by: Lacea Loader
Assistant Director: Media Liaison
Tel: 051 401 2584
Cell: 083 645 2454
E-mail: loaderl.stg@ufs.ac.za  
28 November 2008
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept